Total Payments
$548,574
2024 Payments
$29,175
Companies
60
Transactions
1,040
Medicare Patients
1,775
Medicare Billing
$274,630
Payment Breakdown by Category
Other$424,275 (77.3%)
Travel$67,854 (12.4%)
Consulting$34,365 (6.3%)
Food & Beverage$21,743 (4.0%)
Education$337.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $422,595 | 115 | 77.0% |
| Travel and Lodging | $67,854 | 148 | 12.4% |
| Consulting Fee | $34,365 | 32 | 6.3% |
| Food and Beverage | $21,743 | 736 | 4.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,680 | 1 | 0.3% |
| Education | $337.39 | 8 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $215,054 | 176 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $200,542 | 177 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $81,414 | 116 | $0 (2024) |
| Mirati Therapeutics, Inc. | $23,415 | 16 | $0 (2024) |
| SERVIER PHARMACEUTICALS LLC | $5,553 | 7 | $0 (2024) |
| Genentech USA, Inc. | $3,769 | 68 | $0 (2024) |
| Celgene Corporation | $2,344 | 39 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,941 | 14 | $0 (2024) |
| Taiho Oncology, Inc. | $1,783 | 6 | $0 (2022) |
| Ipsen Biopharmaceuticals, Inc | $1,677 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,175 | 92 | Regeneron Healthcare Solutions, Inc. ($14,054) |
| 2023 | $73,613 | 173 | Regeneron Healthcare Solutions, Inc. ($43,297) |
| 2022 | $156,448 | 226 | GENZYME CORPORATION ($82,436) |
| 2021 | $136,992 | 122 | GENZYME CORPORATION ($94,708) |
| 2020 | $9,465 | 37 | E.R. Squibb & Sons, L.L.C. ($5,559) |
| 2019 | $124,984 | 212 | Regeneron Healthcare Solutions, Inc. ($74,727) |
| 2018 | $16,138 | 110 | E.R. Squibb & Sons, L.L.C. ($11,773) |
| 2017 | $1,759 | 68 | Genentech USA, Inc. ($300.29) |
All Payment Transactions
1,040 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $14.83 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $1,288.98 | General |
| Category: ONCOLOGY | ||||||
| 11/29/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,704.00 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $139.86 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $16.84 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.56 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: Oncology | ||||||
| 11/13/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,704.00 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $18.14 | General |
| 11/06/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $29.47 | General |
| Category: Immunology | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,708.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $27.06 | General |
| Category: Hematology | ||||||
| 09/19/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.55 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2024 | Incyte Corporation | PEMAZYRE (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $15.14 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 09/11/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $12.91 | General |
| Category: Oncology | ||||||
| 09/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 447 | 822 | $126,545 | $66,453 |
| 2022 | 4 | 369 | 744 | $114,511 | $64,168 |
| 2021 | 7 | 415 | 860 | $124,251 | $73,825 |
| 2020 | 5 | 544 | 1,065 | $143,964 | $70,184 |
Total Patients
1,775
Total Services
3,491
Medicare Billing
$274,630
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 79 | 198 | $37,918 | $20,984 | 55.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 89 | 162 | $31,755 | $16,733 | 52.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 91 | 167 | $22,721 | $11,973 | 52.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 122 | $16,677 | $8,108 | 48.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 72 | 91 | $6,910 | $4,160 | 60.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 39 | 64 | $4,804 | $2,838 | 59.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 18 | $5,760 | $1,658 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 76 | 246 | $45,231 | $25,767 | 57.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 87 | 202 | $37,810 | $21,714 | 57.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 69 | 106 | $13,718 | $7,303 | 53.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 37 | 60 | $7,764 | $3,856 | 49.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 51 | 69 | $4,840 | $3,057 | 63.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 36 | 45 | $3,156 | $2,033 | 64.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 16 | $1,992 | $438.39 | 22.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 80 | 229 | $40,184 | $26,183 | 65.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 76 | 168 | $29,761 | $18,658 | 62.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 89 | 189 | $23,250 | $14,447 | 62.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 39 | 88 | $10,826 | $5,791 | 53.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 52 | 73 | $4,504 | $3,560 | 79.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 21 | $6,135 | $1,684 | 27.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 26 | 34 | $2,098 | $1,563 | 74.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 14 | $2,872 | $725.14 | 25.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 17 | 23 | $2,721 | $686.78 | 25.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 11 | 21 | $1,900 | $527.10 | 27.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 110 | 262 | $43,630 | $21,791 | 49.9% |
About Dr. Vikas Dembla, M.D
Dr. Vikas Dembla, M.D is a Internal Medicine healthcare provider based in Spartanburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013128792.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikas Dembla, M.D has received a total of $548,574 in payments from pharmaceutical and medical device companies, with $29,175 received in 2024. These payments were reported across 1,040 transactions from 60 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($422,595).
As a Medicare-enrolled provider, Dembla has provided services to 1,775 Medicare beneficiaries, totaling 3,491 services with total Medicare billing of $274,630. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Spartanburg, SC
- Active Since 05/24/2007
- Last Updated 10/18/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1013128792
Products in Payments
- LIBTAYO (Biological) $376,585
- OPDIVO (Biological) $74,533
- LIBTAYO (Drug) $32,589
- KRAZATI (Drug) $23,415
- TIBSOVO (Drug) $3,795
- TECENTRIQ (Biological) $3,128
- Onivyde (Drug) $1,892
- ONCASPAR (Drug) $1,735
- IMFINZI (Biological) $1,679
- TAS-102 (Drug) $1,575
- SOMATULINE DEPOT (Drug) $1,127
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $1,055
- Stivarga (Drug) $925.20
- KEYTRUDA (Biological) $756.86
- Lenvima (Drug) $725.10
- IMBRUVICA (Drug) $535.22
- Avastin (Biological) $311.12
- Pomalyst (Drug) $284.20
- ICLUSIG (Drug) $204.62
- CYRAMZA (Drug) $181.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Spartanburg
Dr. Tondre Buck, M.d, M.D
Internal Medicine — Payments: $390,444
Internal Medicine $390,444
Michael Humeniuk, Md, MD
Internal Medicine — Payments: $28,166
Internal Medicine $28,166
Suzanne Kovacs, Md, MD
Internal Medicine — Payments: $16,168
Internal Medicine $16,168
Dr. Ikenna Onyebueke, Md, MD
Internal Medicine — Payments: $13,555
Internal Medicine $13,555
Dr. Subhashini Subramaniam, Md, MD
Internal Medicine — Payments: $13,395
Internal Medicine $13,395
Thomas Robinson, Md, MD
Internal Medicine — Payments: $12,037
Internal Medicine $12,037